X4 Pharmaceuticals Announces Public Offering of Common Stock and Pre-Funded Warrants

On October 23, 2025, X4 Pharmaceuticals, Inc. entered into an underwriting agreement with Leerink Partners LLC, Stifel, Nicolaus & Company, Incorporated, and Guggenheim Securities, LLC to issue and sell 45,860,000 shares of its common stock at a public offering price of $2.90 per share. Additionally, the company will issue pre-funded warrants to purchase 700,000 shares of common stock at $2.899 per share. The underwriters have a 30-day option to purchase up to an additional 6,984,000 shares. The net proceeds from the offering are expected to be approximately $145.6 million, after deducting underwriting discounts and commissions and estimated offering expenses. The securities were offered pursuant to a shelf registration statement declared effective on August 24, 2023. The offering is expected to close on October 27, 2025, subject to standard closing conditions.